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ABSTRACT 
Alcohol Consumption in a Preclinical Model of Schizophrenia 
by 
Liza J. Hernandez 
Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the global 
population. Schizophrenia is highly comorbid with other psychiatric disorders such as Alcohol 
Use Disorder (AUD) with a prevalence rate of 27% - 65%, which is significantly higher than 
AUD exhibited by the general population (6%). Research indicates that a higher rate of AUD in 
individuals suffering from schizophrenia may be related to the common neuronal pathways that 
underlie the expression of both disorders. The present study will determine whether the neonatal 
quinpirole (NQ) rodent model of schizophrenia will approximate the human condition and 
exhibit increased EtOH consumption. Rats will be treated neonatally with quinpirole or saline. 
Following the treatment period, rats will be tested for EtOH consumption using a 24-hour two-
bottle free-access paradigm. The proposed research will test the hypothesis that rats neonatally 
treated with quinpirole will consume significantly greater amounts of EtOH than their saline 
counterparts.   
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CHAPTER 1 
INTRODUCTION 
 Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the 
global population (McGrath, Saha, Chant, & Welham, 2008; Khokhar, Dwiel, Henricks, 
Doucette, & Green, 2018). Schizophrenia carries the fourth highest psychiatric disease burden 
worldwide due to early age of onset, lifelong impairments (social, occupational, & cognitive), 
and premature mortality (Miettunen, Immonen, McGrath, Isohanni, & Jääskeläinen, 2018; 
Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015). For instance, a recent meta-analysis 
indicated that individuals with schizophrenia die an average of 13-15 years earlier than non-
schizophrenic individuals due to factors that include: somatic disorders (e.g. cardiovascular 
disease & diabetes), side effects from second-generation antipsychotics (e.g. olanzapine), poor 
lifestyle (e.g. sedentary behavior & poor dietary habits), reduction of health-seeking behavior, 
and increased frequency of illicit and licit drug use (e.g. tobacco, marijuana & alcohol (EtOH); 
Hjorthøj, Stürup, McGrath, & Nordentoft, 2017). However, since schizophrenia is a spectrum 
disorder without a single diagnosis, a wide range of severities as well as a complex etiology (e.g. 
genetic and environmental factors), there is limited understanding of this disorder and further 
research is needed (Horváth & Mirnics, 2015).      
Schizophrenia is characterized by multiple symptom clusters that include positive, 
negative, and cognitive symptoms. Positive symptoms include delusions (believing in something 
that cannot be true), hallucinations (false sensory experiences), disorganized thought or speech, 
and disorganized or abnormal motor behavior (APA, 2014; NIMH, 2016). Negative symptoms 
include blunted affect, avolition (difficulty in initiating or sustaining activities), alogia (reduction 
in verbal communication), anhedonia (decreased enjoyment in pleasurable activities), and 
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asociality (lack of interest in socializing), with the DSM-5 classifying blunted affect and 
avolition as the most prevalent negative symptoms (APA, 2014). Cognitive symptoms are 
manifested as deficits in attention, memory (e.g. working memory and declarative memory), 
executive functioning (e.g. regulation of thoughts, behaviors, and emotions to attain a goal), and 
recognition of having a disorder (i.e. anosognosia). People with schizophrenia have reported 
difficulties in completing educational and vocational tasks due to decreased executive 
functioning (Nestler, Hyman, Holtzman, & Malenka, 2015). 
Overall, the severity of positive and negative symptoms combined with poor social 
functioning is directly correlated with treatment outcome success for individuals suffering from 
schizophrenia (Di Michele & Bolino, 2004). Numerous treatment methods are used to manage 
symptoms, including psychosocial (e.g. psychotherapy, social skills training, and vocational 
rehabilitation) and pharmacological interventions (e.g. antipsychotics; Mayo Clinic, 2018).  
However, numerous factors such as delusion of paranoia, anosognosia, and/ or substance use 
disorders contribute to a failure to maintain an adequate treatment regimen in 50% of patients 
(Haddad, Brain, & Scott, 2014). This is of great concern as noncompliance is associated with 
several negative outcomes including hospitalization, reoccurring positive symptoms, enhanced 
negative symptoms, decreased quality of life, substance abuse, and self-harm (Haddad et al., 
2014). Additionally, there is evidence that adolescent substance abuse (e.g. EtOH and cannabis 
use) is positively correlated with the onset of psychotic symptoms in people later diagnosed with 
schizophrenia, suggesting an important relationship between drug use and disorder progression 
(Hambrecht & Häfner, 1996; Semple, McIntosh, & Lawrie, 2005; van Nimwegen, de Haan, van 
Beveren, van den Brink, & Linszen, 2005).   
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Adolescent Period of Development 
The adolescent period of development is indicative of the developmental stage that 
segregates childhood from adulthood. During this period of development, an abundance of 
alterations are occurring in the brain. Behaviorally, there is an increased tendency to explore and 
seek out euphoric experiences (such as sex and drug use; Walker et al., 2017). The promotion of 
exploration is most likely due to neuronal synaptic pruning and an underdeveloped reward circuit 
(Nimwegen, Haan, Beveren, Brink & Linszen, 2005). During the reorganization of this circuitry 
adolescents not only have an elevated risk and enhanced reward-sensitivity towards using drugs 
but also display a reduction in sensitivity toward the aversive effects of drugs (Doremus-
Fitzwater & Spear, 2016).  
 
Schizophrenia Comorbid with Alcohol Use Disorder 
 Research indicates that individuals diagnosed with schizophrenia have a significantly 
higher risk of developing an alcohol-use disorder (AUD; APA, 2014; Green, Drake, Brunette, & 
Noordsy, 2007; Khokhar et al., 2018) however, the literature differs drastically on the prevalence 
of comorbid schizophrenia and AUD, ranging from 27% (Thoma & Daum, 2013) to 65% 
(Volkow, 2009). Regardless of the specific prevalence, it is clear that individuals suffering from 
schizophrenia are at a much greater risk to develop a comorbid AUD than the general population 
(6.2%; NIAAA, 2018). Schizophrenia comorbid with AUD is typically exhibited by males that 
experienced an earlier onset of the disorder and leads to greater severity of extrapyramidal, 
positive symptoms (Thoma & Daum, 2013). Moreover, comorbid expression of schizophrenia 
and AUD is associated with an increased likelihood of several negative outcomes including; 
lower quality of life, increased treatment non-compliance rates, increased violent behavior, risk 
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of suicide, homelessness, and hospitalization (Green et al., 2007; Thoma & Daum, 2013; 
Khokhar et al., 2018). 
There are two predominant hypotheses as to the high prevalence of comorbid 
schizophrenia and AUD. An initial theory, the self-medicating hypothesis (SMH), suggests that 
people abuse drugs deliberately based on the psychopharmacological effects that provide relief 
from the symptoms associated with schizophrenia (Chambers, Krystal, & Self, 2001; Goswami, 
Mattoo, Basu, & Singh, 2004; Khantzian, 1985). For instance, people with schizophrenia have 
reported that EtOH consumption alleviates positive and negative symptoms including, 
hallucinations, delusions, anhedonia, asociality, and anxiety (Addington & Duchak, 1997; 
Chambers, Krystal, & Self, 2001; Thoma & Daum, 2013). A second theory, the primary 
addiction hypothesis, postulates that individuals suffering from schizophrenia have a heightened 
risk of developing an AUD as both disorders affect common brain pathways (Volkow, 2009). 
Specifically, the atypical neuropathology of schizophrenia also produces alterations in the 
regulation of positive reinforcement, incentive salience, behavioral inhibition, and addictive 
behavior due to the dysregulation of the mesocorticolimbic circuitry (Chambers, Krystal, & Self, 
2001). It is important to delineate the nature of the disruptions in the neuropathology pertaining 
to schizophrenia to further understand the enhanced comorbidity of SUDs in this population as 
well as to research novel treatment methods.   
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CHAPTER 2 
LITERATURE REVIEW  
Nestler and colleagues (2015) indicated that schizophrenia and AUD are independent 
disorders derived from abnormalities primarily in the mesocorticolimbic circuitry. The 
mesocorticolimbic dopamine (DA) pathway has been thoroughly established in both humans and 
nonhuman animals, to be involved in the manifestation of several symptoms associated with 
schizophrenia, as well as motivation and reward, (for review see Brisch et al., 2004; see also 
Fallon & Moore, 1978; Oleson & Roberts, 2018; Wise, 2004) and has been further divided into 
the mesolimbic and the mesocortical pathways (Chinta & Andersen, 2004). Both pathways are 
comprised predominantly of DA neurons in the ventral tegmental area (VTA) projecting to 
various regions of the brain including the nucleus accumbens (Acb), olfactory tubercles, 
amygdala, hippocampus, septum, prefrontal cortex (PFC), cingulate cortex, and perirhinal cortex 
(Adinoff, 2004; Chinta & Andersen,2004; Gardner, 2011; Olds, & Milner, 1954; Wise, & 
Bozarth, 1984). Research has found that DA neuronal activation in the mesolimbic pathway is 
primarily associated with pleasurable stimuli (e.g. food, sex, social interactions, or drugs; for 
review see Ikemoto, 2007). DA signaling within the mesocortical pathway has been linked to 
executive functions such as working memory, goal-directed behaviors, and attention (Siddiqui, 
Chatterjee, Kumar, Siddiqui, & Goyal, 2008). Thus, disruption of the mesocorticolimbic circuit 
has been implicated in numerous disorders, including schizophrenia and AUD (Nestler et al., 
2015).  
Mesocorticolimbic Circuitry and Schizophrenia 
 Malfunction within the mesolimbic pathway contributes to the positive symptoms of 
schizophrenia (e.g. hallucinations and delusions; Nestler et al., 2015). Evidence suggesting the 
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involvement of this pathway in schizophrenia was first reported when DA D2 receptor (D2-R) 
antagonist administration resulted in a significant reduction of psychoses in patients diagnosed 
with schizophrenia (Chambers et al., 2001; Crow, Deakin, & Longden, 1977). Additionally, 
psychostimulants have been shown to induce psychotic-like effects in human and animal subjects 
causing DA dysregulation (Chambers et al., 2001; Connell, 1957; Laviolette, 2007; Lodge & 
Grace, 2007; McCollum & Roberts, 2015). Using functional magnetic resonance imaging 
(fMRI), patients with schizophrenia were asked to perform a memory retrieval task, and 
individuals who did not display hippocampal activation during the task also exhibited 
psychosocial impairments (Weiss et al., 2003).  Increased amygdala activation is prevalent in 
schizophrenia, causing abnormal classifications of aversive or threating stimuli (Kumakura et al., 
2007). Similarly, an increase of amygdala activation in schizophrenia patients induces a 
heightened bias towards aversive processing by over-emphasizing emotions associated with a 
specific sensory stimulus leading to delusions (Laviolette, 2007; Pankow et al., 2013).         
The mesocortical pathway has been implicated in both the negative and cognitive 
symptoms of schizophrenia. Aberrations in neural processing of the PFC contribute to decreased 
motivation, drive, and hygiene, as well as asociality and impairment of intuition and judgment 
(Knable & Weinberger, 1997). Evidence suggests that negative and cognitive symptoms are a 
result of hypoactivity of DA released from the VTA to the PFC, as well as dysfunction of the DA 
D1 receptor, which primarily mediates DA transmission (Chambers et al., 2001; Knable & 
Weinberger, 1997; McCutcheon, Abi-Dargham, & Howes, 2019; Slistein et al., 2015; Thoma & 
Daum, 2013). Disruption in DA transmission observed in schizophrenia patients has been 
associated with abnormalities in “top-down processing” of the PFC ultimately affecting 
cognition (Lesh, Niendam, Minzenberg, & Carter, 2011). Specifically, researchers conducted 
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fMRI studies to indicate that the dorsolateral PFC (DLPFC), anterior cingulate cortex, and the 
mediodorsal thalamus are DA deficient possibly leading to cognitive deficits in schizophrenia 
patients (Minzenberg, Laird, Thelen, Carter, & Glahn, 2009).    
Mesocorticolimbic Circuitry and AUD 
The mesolimbic pathway is believed to mediate the reinforcing effects of EtOH, as well 
as play a key role in EtOH craving and relapse (For review see: Gilpin & Koob, 2008; see also 
Eisenhardt, Leixner, Luján, Spanagel, & Bilbao, 2015; Imperato & Di Chiara, 1986). EtOH has 
been shown to stimulate DA neurons that project from the VTA to the Acb and the amygdala (Di 
Chiara & Imperato, 1988; Engel & Jerlhag, 2014; Fadda, Mosca, Colombo, & Gessa, 1989; 
Yoshimoto et al., 2000). For instance, EtOH enhances the firing rate of VTA DA neurons 
stimulating DA release in the shell of the Acb (AcbSh; for review see Deehan, Brodie, & Rodd, 
2013; see also Bassareo et al., 2003; Deehan et al., 2016; Engel & Jerlhag, 2014). EtOH 
consumption has also been found to enhance associative learning by stimulating DA 
transmission to the amygdala, thereby increasing the emotional salience of EtOH (Di Chiara et 
al., 1999). Furthermore, EtOH interacts with other neurotransmitters causing an indirect increase 
of extracellular DA (Engel & Jerlhag, 2014). Critically, co-infusion of compounds that inhibit 
DA signaling (e.g., DA D2-receptor agonist, quinpirole)  in this pathway produce reductions in 
the self-administration of EtOH into the posterior VTA suggesting that the reinforcing properties 
of EtOH in the mesolimbic DA pathway are dependent on DA neuronal activation (Rodd et al., 
2004, 2005).  
The mesocortical pathway has also been implicated in drug-seeking behaviors and drug 
dependence and has been shown to control compulsory behaviors directed toward obtaining 
EtOH, the suppression of thoughts associated with EtOH, and “hyper-responsiveness” to EtOH-
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associated stimuli (Adinoff, 2004; Feltenstein & See, 2013). Acute EtOH administration results 
in a decrease in PFC functioning that contributes to deficits in planning and spatial recognition 
tasks (Abernathy, Chandler, & Woodward, 2010; Weissenborn & Duka, 2003). Data indicate 
that the rewarding effects of acute EtOH intake are, in part, mediated by DA release within the 
PFC (Lammel et al., 2008; Trantham-Davidson & Chandler, 2015). However, chronic EtOH 
intake is associated with a decrease in DA signaling from the VTA to the PFC producing 
anhedonia and blunted reward processing during withdrawal (Trantham-Davidson & Chandler, 
2015). Researchers have found that AUD causes decreased grey matter in the DLPFC which 
results in a decrease in neuronal processing (Jernigan et al., 1991; Yang et al., 2016). 
Unfortunately, the research is lacking as to the biological underpinning of decreased DA 
transmission during chronic EtOH exposure (Trantham-Davidson & Chandler, 2015).               
Modeling in Preclinical Research 
Gestational Methylazoxymethanol Acetate Model (MAM) 
The gestational MAM model has been extensively used as a developmental model of 
schizophrenia (Ratajczak, Woźniak, & Nowakowska, 2013). The model was developed in 
response to research suggesting that schizophrenia is attributed to significant gestational distress 
(e.g. influenza or malnutrition) to the fetus, during the second trimester of pregnancy (Jones, 
Watson, Fone, 2011). MAM is a neurotoxin that inhibits DNA synthesis, causing apoptosis in 
cells that are actively replicating DNA (Talamini, Koch, Ter Host, & Korf, 1998). Interestingly, 
MAM does not affect glial cells or peripheral organs making it a practical method for modeling 
schizophrenia (Jones et al., 2011; Ratajczak et al., 2013). Pregnant female rats are treated with 
MAM on gestational day (GD) 17 when the fetus has completed brain cortex proliferation, but 
subcortical regions are still undergoing development (Jones et al., 2011). The treatment causes 
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reductions in the size of several regions of the neocortical and limbic systems (medial prefrontal 
cortex, entorhinal cortex, hippocampus, and occipital cortex), which is consistent with the 
clinical histopathology observed in schizophrenia (Talamini et al., 1998; Lodge & Grace, 2009; 
Jones et al., 2011; Ratajczak et al., 2013). However, studies have not been able to exhibit an 
alleviation of symptoms caused by MAM when rodents are administered typical or atypical 
antipsychotics (For review see: Jones, 2011). There is a limited amount of research conducted on 
female rats exposed to MAM during GD 17 (Perez, Donegan, & Lodge, 2019), which is 
concerning given that schizophrenia affects males and females equally (Li, Ma, G. Wang, Yang, 
& C. Wang, 2016). Finally, MAM is a known carcinogen and exposure is potentially hazardous 
to laboratory personnel, thus extreme caution must be utilized when handling the compound 
(Lodge, 2013).     
Neonatal Ventral Hippocampal Lesion Model (NVHL) 
The NVHL model was developed to approximate abnormalities in the ventral 
hippocampus (VH) that have been reported in people suffering from schizophrenia (Lipska, 
Jaskiw, Chrapusta, Karoum, & Weinberger, 1992). On postnatal day (PND) 7 rats are bilaterally 
infused with ibotenic acid in the VH causing irreversible ablation and disruption of the 
hippocampal formation (For review see: Lipska & Weinberger, 2002; see also Lipska, Jaskiw, & 
Weinberger, 1993). The VH lesions progressively produce DA-related behavioral and molecular 
changes during late adolescence into early adulthood that approximate the clinical population 
with schizophrenia such as increases in mesolimbic DA activity and inhibition of cortical DA 
activity (Khokhar & Todd, 2018; Lipska & Weinberger, 1995; Tseng, Chambers, & Lipska, 
2009). It has also been noted that mortality rates for the NVHL surgery are approximately 15% 
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(Richtand et al. 2005) and 30-33% of rodents show unilateral damage leading to failure to reach 
the histopathological criteria of schizophrenia (Jones et al., 2011).    
Neonatal Quinpirole Model of Schizophrenia 
Quinpirole is a DA D2/D3-receptor agonist that creates a lifelong enhanced sensitization, 
but not overall quantity, of D2 receptors (D2-R) following chronic intraperitoneal (i.p.; 1mg/kg) 
injections during the neonatal period (PND 1-21; Kostrezewa, 1993; Peterson et al., 2017; 
Rodrigo et al., 2011). The enhanced sensitization of D2 receptors is behaviorally manifested as 
stereotypy (i.e. clockwise lateral movement), and abnormalities in locomotion, learning, and 
memory (Kostrzewa, Nowak, Brus, & Brown, 2016; Rodrigo et al., 2011), which is also 
observed in the human population with schizophrenia (For review see: Weidenauer et al., 2017). 
The unchanged quantity of D2-R is important because this aspect of the model is also consistent 
with findings in the clinical population (Kostrezewa et al., 2016). DA receptor sensitivity can be 
behaviorally measured in increases of locomotion, yawning, stereotypies, and vertical jumping, 
deficits can also be observed in cognitive tasks (Kostrezewa, 1993).  
 The neonatal quinpirole (NQ) model exhibits face validity concerning atypical behaviors. For 
example, D2 supersensitization in rodents creates deficits in prepulse inhibition (PPI; 
sensorimotor gating; Kostrezewa et al., 2016; Maple, Smith, Perna, & Brown, 2015) which is 
indicative of deficits in information processing that are associated with schizophrenia (Brisch et 
al., 2014; Maple et al., 2015). In humans diagnosed with schizophrenia, PPI deficits are directly 
correlated with the severity of positive symptoms which are markedly reduced by antipsychotic 
drugs (Meincke et al., 2004). Similarly, PPI deficits in NQ rats can be attenuated by the 
administration of an antipsychotic (Maple et al., 2015).    
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Construct validity is demonstrated when a preclinical model and a human disorder share 
a common biological factor, such as a genetic mutation (Kostrezewa et al., 2016). In the NQ 
model, brain-derived neurotrophic factor (BDNF) is significantly reduced, similar to humans 
with schizophrenia (Maple et al., 2015). BDNF is imperative for CNS neurogenesis by 
increasing cell survival (Durany et al., 2001) and disruption in BDNF levels is believed to 
contribute to the neuropathology of schizophrenia in the affected brain regions (Favalli, Li, 
Belmonte-de-Abreu, Wong, & Daskalakis, 2012). The NQ model displays deficits in 
hippocampal BDNF expression resulting in cognitive aberrations (Brown, Gass, & Kostrzewa, 
2002; Thacker et al., 2006). Coincidentally, Durany and colleagues (2001) observed 
hippocampal BDNF deficits in postmortem patients diagnosed with schizophrenia. In the NQ 
model, microdialysis studies have indicated significant increases in DA outflow of the Acb 
compared to control rats, which is similar to the observed increased accumbal DA levels in the 
clinical population (Cope et al., 2010).   
Predictive validity is established when a preclinical model successfully responds to 
human treatment (Belzung & Lemoine, 2011). The common treatment for schizophrenia is the 
administration of antipsychotics, such as haloperidol (typical antipsychotic) or clozapine and 
olanzapine (atypical antipsychotic; Patel, Cherian, Gohil, & Atkinson, 2014). The function of 
typical antipsychotics is to block DA from binding to D2-R resulting in reductions of DA 
transmission to the Acb (Seeman, 2002). The administration of antipsychotics in NQ rats creates 
a marked reduction of cognitive symptoms demonstrated in Morris Water Maze (MWM) 
performance (Thacker et al., 2006). The MWM is a hippocampal spatial learning task for 
rodents, in which there is a platform submerged in water and rodents must use spatial navigation 
and reference memory to find the platform for a set number of trials (Morris, 1984; Vorhees & 
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Williams, 2006).  When NQ rats were administered olanzapine in adulthood, they exhibit an 
alleviation of cognitive deficits demonstrated by an increased performance on the MWM 
(Thacker et al., 2006). Additionally, the conditioned place preference (CPP) task can 
demonstrate the associative properties formed nicotine and the context in which the rats received 
the drug (Brown et al., 2018; Perna, Henderson, Bruner, & Brown, 2011). The CPP paradigm 
implements the principles of classical conditioning to assess the associative properties of a 
stimulus by measuring the amount of time spent in a particular area that was paired with the 
stimulus (Tzschentke, 2007). Interestingly, the administration of haloperidol blocked the 
associative effects of nicotine in both the NQ rats and the saline rats, but clozapine only blocked 
associative effects of nicotine in NQ treated animals (Brown et al., 2018a).   
Animal Models of Schizophrenia and AUD  
Several studies investigating the comorbidity of SUDs using animal models of 
schizophrenia have provided mixed findings (For review see: Ng, McGirr, Wong, & Roder, 
2013; see also Amitai & Markou, 2009; Rezvani, Kholdebarin, Dawson, & Lavin, 2008). Only 
two models have been studied relative to SUDs. Studies utilizing the NVHL model of 
schizophrenia have found that VH lesioned rats will self-administer multiple substances (e.g. 
cocaine, methamphetamine, nicotine, and EtOH) and become sensitized to the substances more 
quickly than control rats in a similar fashion to the human population exhibiting comorbid 
schizophrenia and SUD (Berg, Sentir, Bell, Engleman, & Chambers, 2015; Brady, McCallum, 
Glick, & O’Donnell, 2008; Chambers & Self, 2002; Khokar & Todd, 2018). Evidence also exists 
that adolescent EtOH consumption produces an increase in adult EtOH drinking in NVHL 
animals (Jeanblanc et al. 2014). This correlates with human schizophrenia research indicating 
that prodromal EtOH exposure in adolescence is associated with AUD in adulthood (Jeanblanc et 
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al. 2014; Khokar & Todd, 2018). To date, however, the majority of research on drug use in the 
NQ model has focused on the addictive properties of stimulants (e.g. nicotine and amphetamines; 
Cope et al., 2010; Peterson et al., 2017). Prior to the current study, there has not been any work 
to analyze whether EtOH consumption would be affected in the NQ model of schizophrenia. 
Current Study 
The prevalence of AUD in people diagnosed with schizophrenia is significantly higher 
than the general population, with rates reaching upwards of 65% (Volkow, 2009). The neuronal 
mechanisms associated with these disorders are not well understood, therefore further research is 
necessary. This project seeks to analyze ethanol drinking behavior in a preclinical model of 
schizophrenia as a preliminary step to potentially understand the underlying aberrations in 
neurotransmitter signaling that manifest in schizophrenia and AUD. The purpose of assessing 
EtOH consumption in this model is to produce supplementary information on the common 
neuronal pathways that intersect schizophrenia and AUD. Based on the literature review above 
the hypotheses of the proposal are as follows:  
• H1: The neonatal quinpirole model will prove to be predictively valid in assessing 
EtOH consumption in a preclinical model of schizophrenia comorbid AUD.   
• H2a: Rats neonatally treated with quinpirole during PND 1-21 will consume 
significantly more EtOH than their saline counterparts during both exposure periods 
(PND 28-42, PND 75-120).   
• H2b: Rats neonatally treated with quinpirole during PND 1-21 will significantly 
consume more EtOH than their saline counterparts during the first exposure period 
(PND 28-42).  
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• H2c: Rats neonatally treated with quinpirole during PND 1-21 will significantly 
consume more EtOH than their saline counterparts during the second exposure 
period (PND 75-120).  
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CHAPTER 3 
METHODS  
Subjects 
 Adolescent NQ female Sprague Dawley rats were 22 days old when obtained from 
Brown Laboratory (Mountain Home, TN) and group housed until PND 28. Male and female 
adult Sprague Dawley breeders were ordered (Envigo Inc., Indianapolis, IN) and housed together 
until females are approximately at gestational day (GD) 17 at which point pregnant dams were 
singly housed. Rat pups were born at approximately GD 22 which represented post-natal day 
(PND) 0. The rat pups resided with the female dam until PND 21 when they were weaned, and 
group housed until PND 28. Animals were derived from four litters and group assignments were 
based on neonatal treatment and EtOH concentration exposure in adolescence and adulthood 
(Table 1). Animals were housed in a reverse 12-h light/dark cycle. Food and water were 
available ad libitum throughout the experiment. All procedures were approved by East 
Tennessee State University Animal Care and Use Committee prior to initiation.    
Table 1.  
Group Assignment Table  
 Quinpirole (NQ 10-20) 
n = 10 
Quinpirole (NQ 10-10)  
n = 10 
Saline  
n = 10  
Adolescent Ethanol 
Concentration  10% (v/v) 10% (v/v) 10% (v/v) 
Adulthood Ethanol 
Concentration 20% (v/v) 10% (v/v) 20% (v/v) 
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Drugs and Solution 
 Quinpirole hydrochloride (Sigma Aldrich, St. Louis, MO) was diluted with 0.9% (w/v) 
isotonic saline (Ricca Chemical Company, Arlington, TX) to form a 1 mg/kg concentration. 190 
proof EtOH (Pharmco by Greenfield Global, Inc., Shelbyville, KY) was diluted with deionized 
water to 10% (v/v) and 20% (v/v) EtOH concentrations.  
Procedure 
Rats were given single daily intraperitoneal (i.p.) injections of either quinpirole HCL (1 
mg/kg) or 0.9% saline (1 mg/kg) based on body weight from PND 1-21. On PND 21 rats were 
weaned from the dam and group-housed (3-4 to a cage).  On PND 28, all rats were singly housed 
in order to assess adolescent EtOH consumption.   
Two-bottle Choice Task with Two Exposure Periods  
Animals were tested for EtOH consumption using a 24-hour 2 bottle free-access 
paradigm. The timing of EtOH access approximated previous research examining EtOH 
consumption in animal models of schizophrenia (Jeanblanc et al., 2014). Rats were exposed to 
EtOH during two developmental periods. The first exposure occurred during adolescence (PND 
28-42) and the second occurred during adulthood (PND 75-120). During both exposure periods, 
rats were provided with two Ancare (Bellmore, NY) screw top bottles on their home cage. In the 
first exposure period (PND 28-42) the bottles contained either 10% (v/v) EtOH or tap water. On 
PND 42 the EtOH bottles were removed and the rats had access only to tap water. The second 
exposure period (PND 75-120) the bottles contained either 10% EtOH (NQ 10-10), 20% EtOH 
(v/v; NQ 10-20 & Saline) or tap water. On PND 90 the EtOH bottles were removed and the rats 
had access to tap water only. During the two exposure periods, food and fluid intake and body 
weights were recorded daily.   
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Statistical Analysis 
 Daily readings of body weight and the consumption of EtOH, water, and food were 
recorded into a spreadsheet using Microsoft Excel (2019). Daily means and standard errors of 
consumption (EtOH, water, and food) were calculated for each group. To properly assess EtOH 
intake, ml of EtOH consumed was converted to grams of EtOH consumed by animal body 
weight in order to obtain the amount of intake relative to the animal's body weight.  Daily intake 
graphs were created using GraphPad Prism 6 (2017). EtOH intake data was organized into JASP 
0.9.2 (2019) to investigate the effect of EtOH consumption during two Exposure Periods 
(Adolescence vs. Adulthood) by Neonatal Treatment (NQ 10-20, NQ 10-10, & Saline) and a 
repeated-measures ANOVA with Neonatal Treatment as the between-subjects factor and 
Exposure Period as a within-subject factor was fitted to the data. Since the exposure period was a 
repeated measure of EtOH consumption (g/kg). The alpha criterion was set at p < 0.05 to further 
investigate significant interactions. Outliers were defined as data anomalies that were two 
standard deviations above or below the mean. When outliers were identified the datapoint was 
reverted to the mean. In order to determine the significance of body weights, food and water 
consumption on individual days of exposure, between the three groups, a one-way ANOVA was 
fitted to the data using aov function (stats package) and PostHocTest (DescTools; Signorell et al., 
2019) in R 3.6.0 (2019). Since there were 28 days of exposure, p-values acquired from the one-
way ANOVAs were adjusted using the R package stats (2019) with Benjamini – Hochberg 
corrections in order to decrease the false-discovery rate (Benjamini & Hochberg, 1995).  
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CHAPTER 4 
RESULTS  
The descriptive measurements for EtOH consumption are presented in Table 1. An 
ethanol bottle leaked causing an animal in the NQ 10-20 group to display larger than possible 
ethanol consumption, thus this data point was reverted to the group mean (Table 2). A two-way 
ANOVA (Days of EtOH Exposure by Neonatal Treatment Group) with repeated measures was 
fit to the data. Mauchly's test indicated that the data violated the sphericity assumption, therefore 
sphericity corrections using Greenhouse – Geisser were implemented and are shown in Table 3. 
The repeated measures ANOVA demonstrated an increase in EtOH consumption, as it revealed a 
significant between-subjects effect of Neonatal Treatment (F(2,27) = 4.259, p = 0.025, η2 = 0.240), 
a significant within-subjects effect of Days of EtOH Exposure (F(8.926, 241.001) = 7.717, p < 0.001, 
η2 = 0.191; Figure 1), and an interaction effect of Neonatal Treatment by Days of EtOH 
Exposure (F(17.852, 241.001) = 2.813, p < 0.001, η2 = 0.139). A Benjamini-Hochberg post hoc test 
revealed that the NQ 10-10 and Saline groups differed significantly at p = 0.020. Pairwise 
comparisons were fit to the data to assess group differences of EtOH consumption during 
individual days (Figure 2) indicating that NQ 10-10 group consumed more EtOH than NQ 10-20 
and Saline groups on PND 83; 85-87; 89 (p’s < 0.05, Fig. 2) and NQ 10-10 group had a greater 
intake of EtOH than the Saline group on PND 84 (p’s < 0.05, Fig. 2). NQ 10-20 group consumed 
more EtOH than NQ 10-10 group on PND 77-78 (p’s < 0.05, Fig 2).  
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Figure 1. Overall mean (+ SEM)  EtOH consumption between Exposure Period. * represents 
Adulthood mean EtOH consumption is significantly greater than Adolescent mean 
consumption, p < 0.05.  
Adolescence Adulthood 
Exposure Period  
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Body Weight and Food and Water Consumption 
Bodyweight and food and water consumption (grams) during adolescence and adulthood 
were examined between Neonatal Treatment Groups (NQ 10-20 vs. NQ 10-10 vs. Saline). Means 
and standard deviations of Exposure Period between Treatment group are presented in Table 3. 
Body Weights  
A repeated-measures ANOVA (Days of EtOH Exposure by Neonatal Treatment Group) 
was fit to the data. Mauchly's test indicated that the data violated the sphericity assumption, 
therefore sphericity corrections using Greenhouse – Geisser were implemented. The repeated 
measures ANOVA demonstrated an increase in body weight, as it revealed a significant 
Figure 2. Treatment Group mean (+ SEM) of EtOH consumption during each day of EtOH 
exposure. Figure A represents the Adolescent Exposure Period while Figure B denotes the 
Adulthood period. There was a significant interaction effect between the NQ #2 & Saline, 
denoted by * in the legend. @ represent NQ 10-20 being significantly higher than NQ 10-10 
& Saline. # represent NQ 10-20 being significantly higher than NQ 10-10. * represent NQ 
10-10 being significantly higher than NQ 10-20 and Saline and $ represent NQ 10-10 being 
significantly higher than Saline. Significance determined through pairwise comparisons 
using Benjamini-Hochberg corrections (p’s < 0.05).    
 
 
10-20 
10-10 
@ 
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between-subjects effect of Neonatal Treatment (F(2,27) = 7.261, p = 0.003, η2 = 0.350), a 
significant within-subjects effect of Days of EtOH Exposure (F(1.448, 39.103) = 2348.90, p < 0.001, 
η2 = 0.980), and an interaction effect of Neonatal Treatment by Days of EtOH Exposure (F(2.897, 
39.103) = 10.01, p < 0.001, η2 = 0.008). A post hoc Benjamini-Hochberg test revealed that the NQ 
10-20 and Saline groups differed significantly at p = 0.003. 
 Pairwise comparisons using one-way ANOVAs were fit to each day and the p values 
were adjusted using Benjamini-Hochberg corrections. The comparisons indicated that the NQ 
10-20 group weighed significantly more than the Saline group during the Adolescent Exposure 
Period on PND 37 - 41 (p’s < 0.043, Fig. 3), with mean weight differences of 21.072 grams.  
During Adulthood and PND, 42 NQ 10-20 and NQ 10-10 groups weighed significantly more 
than Saline groups on PND 76 - 89 (p’s < 0.001, Fig. 3), with mean weight differences of 41.816 
grams.  
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Food Intake 
 The analysis of food consumption commenced on PND 34 rather than PND 28 
because the pups were recently weaned and separated from their siblings. To view whether food 
intake differed, a two-way ANOVA (Days of EtOH Exposure by Neonatal Treatment Group) 
with repeated measures was fit to the data. Mauchly's test indicated that the data violated the 
sphericity assumption, therefore sphericity corrections using Greenhouse – Geisser were 
implemented. The repeated measures ANOVA demonstrated a difference in food consumption, 
as it revealed a significant between-subjects effect of Neonatal Treatment (F(2,27) = 8.159, p = 
0.002, η2 = 0.377), a significant within-subjects effect of Days of EtOH Exposure (F(7.497, 202.427) 
= 6.154, p < 0.001, η2 = 0.145), and an interaction effect of Neonatal Treatment by Days of 
Figure 3. Treatment Group mean (+ SEM) body weight during each day of EtOH exposure. 
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period. 
There was a significant interaction effect between the NQ 10-20 & Saline, denoted by * in the 
legend. ^ represent NQ 10-20 being significantly higher than Saline. * represents NQ 10-20 & 
NQ #2 being significantly higher than Saline. Significance determined through pairwise 
comparisons using Benjamini-Hochberg corrections (p’s < 0.05).    
 
10-20 
10-10 
 *
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EtOH Exposure (F(14.995, 202.427) = 4.630, p < 0.001, η2 = 0.218). A post hoc Tukey’s test revealed 
that the NQ 10-20 and NQ 10-10 groups differed significantly at p = 0.006 and that NQ 10-20 
and Saline groups differed significantly at p = 0.004. 
Pairwise comparisons were fit to the data to assess group differences of food 
consumption during individual days (Figure 4) indicating that the NQ 10-20 group consumed 
significantly more food than the NQ 10-10 and the Saline group during the Adolescent Exposure 
Period on PND 42 (p’s < 0.05, Fig. 4). During Adulthood the NQ 10-20 group consumed 
significantly more food than the NQ 10-10 and Saline groups on PND 77, 80 and 88 (p’s < 
0.028, Fig. 4). NQ 10-20 and NQ 10-10 groups consumed significantly more than the Saline 
group on PND 83 (p = 0.030, Fig. 4). NQ 10-20 and Saline groups consumed significantly more 
than the NQ 10-10 group on PND 86 (p < 0.001, Fig. 4).   
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Water Consumption 
 
To assess whether water intake differed, a two-way ANOVA (Days of EtOH Exposure by 
Neonatal Treatment Group) with repeated measures was fit to the data. Mauchly's test indicated 
that the data violated the sphericity assumption, therefore sphericity corrections using 
Greenhouse – Geisser were implemented. The repeated measures ANOVA demonstrated a 
difference in water consumption, as it revealed a significant between-subjects effect of Neonatal 
Treatment (F(2,27) = 4.459, p = 0.021, η2 = 0.248), a significant within-subjects effect of Days of 
EtOH Exposure (F(9.671, 261.117) = 15.322, p < 0.001, η2 = 0.300), and an interaction effect of 
Neonatal Treatment by Days of EtOH Exposure (F(19.342, 261.117) = 4.389, p < 0.001, η2 = 0.172). 
 
Figure 4. Treatment Group mean (+ SEM) food intake during each day of EtOH exposure. 
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period. 
There was a main effect of interaction in that NQ 10-20 > NQ 10-10 & Saline. $ represents 
NQ 10-20 being significantly higher than NQ 10-10 & Saline. * represent NQ 10-20 & NQ 
10-10 being significantly higher than Saline. @ represent NQ#1 and Saline being significantly 
higher than NQ 10-10. Significance determined through pairwise comparisons using  
Benjamini-Hochberg corrections (p’s < 0.05).  
PND 
10-20 
10-10 
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A post hoc Tukey’s test revealed that the NQ 10-20 and Saline groups differed significantly at p 
= 0.029. Pairwise comparisons were fit to the data to assess group differences of water 
consumption during individual days (Figure 5) indicating that the Saline group consumed 
significantly more water than the NQ 10-20 and/or NQ 10-10 groups during Adulthood on PND 
76, 78, 81, 84, 85, 87, and 89 (p’s < 0.01, Fig. 5) with a mean consumption difference of 8.626 
grams. NQ 10-20 and Saline groups consumed significantly more water than the NQ 10-10 
group on PND 86 (p < 0.001, Fig. 5) with a mean consumption difference of 12.056 grams.    
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Treatment Group mean (+ SEM) water consumption during each day of EtOH exposure. 
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period. There 
was a main effect of interaction between the NQ10-20 & Saline, denoted by * in the legend. $ 
represent Saline being significantly higher than NQ 10-20. * represent Saline being significantly 
higher than NQ 10-20 & NQ 10-10. @ represent NQ#1 10-20 & Saline being significantly higher 
than NQ 10-10. Significance determined through pairwise comparisons using Benjamini-Hochberg 
corrections (p’s < 0.05).   
 
PND 
10-20 
10-10 
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Table 2.  
Descriptive statistics for EtOH consumption 
Note. An outlier was found in the adolescent quinpirole group; thus, it was reverted to the group 
mean. Changes in the Quinpirole group mean before and after adjusting the outlier is indicated 
above, in red. 
Descriptive Statistics 
 
Adolescent EtOH 
Consumption 
(with bottle leak) 
Adolescent Adjusted 
EtOH Consumption 
(without bottle leak) 
Adult EtOH 
Consumption 
 NQ 10-20 NQ 10-10 Saline NQ 10-20 NQ 10-10 Saline NQ 10-20 NQ 10-10 Saline 
N 10 10 10 10 10 10 10 10 10 
Mean 2.329 2.519 1.608 2.053 2.519 1.608 3.096 3.864 2.657 
SD 1.242 1.024 0.3192 0.7833 1.024 0.3192 0.9942 0.5579 0.7492 
Min 1.273 1.275 1.14 1.273 1.275 1.14 1.423 3.029 1.664 
Max 5.084 4.213 2.21 3.553 4.213 2.21 4.249 4.734 4.133 
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Table 3.  
Repeated measures ANOVA for ETOH consumption 
 
Between Subjects Effects  
   Sum of Squares  df  
Mean 
Square  F  p  η²  
Neonatal 
Treatment  
 126.0  2  63.000  4.259  0.025  0.240 
Residual   399.4  27  14.79        
Note.  Type III Sum of Squares  
 
  
Within Subjects Effects 
 Sum of Squares df Mean Square F p η² 
EtOH Exposure 309.8 8.926  (26.000) 
34.710 
(11.916) 7.717 
6.565e -10 
(7.163e -25) 0.191 
EtOH Exposure * 
Neonatal Treatment 225.9 
17.852 
(52.000) 
12.653 
(4.344) 2.813 
1.900e -4 
(1.186e -9) 0.139 
Residual 1084.0 241.001 (702.000) 
4.498 
 (1.544)    
Note. Type III Sum of Squares. Mauchly’s test of sphericity indicates that the assumption of 
sphericity is violated (p < 0.05). Greenhouse – Geisser corrections are noted in the table with values 
prior to the corrections in parentheses.  
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  Food 
Consumption (g) 
 Water 
Consumption (g) 
 Body 
Weight (g) 
  Ado Adult  Ado Adult  Ado Adult NQ 10-20 (n = 10)          
 Mean 13.335 15.223  16.149 18.926  111.236 235.712 
 SD 1.170 1.010  4.224 4.195  9.431 12.022 
 Min 11.5 13.827  10.664 14.400  96.329 213.014  Max 15.457 16.700  23.750 28.233  124.764 251.357 
NQ 10-10 (n = 10)           Mean 12.154 13.417  16.743 19.225  102.246 224.125  SD 2.020 1.459  3.832 4.066  22.915 35.733  Min 9.679 11.643  11.821 13.036  80.393 183.571  Max 15.429 15.742  24.179 27.628  138.929 289.429 Saline (n = 10)          
 Mean 12.218 13.517  19.061 24.674  92.979 193.896 
 SD 0.819 0.937  3.165 3.381  4.216 9.429 
 Min 10.633 12.536  14.464 18.451  87.571 180.607 
 Max 13.400 15.750  25.679 30.393  99.464 205.893 
 Note. Ado = adolescent exposure period; Adult = adult exposure period.  
Table 4.  
Descriptive Statistics for Food, Water, and Body Weight  
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CHAPTER 5 
DISCUSSION 
 The purpose of this experiment was to investigate EtOH consumption in the NQ model 
of schizophrenia using the two-bottle 24 hr access paradigm with adolescent and adulthood 
exposure periods. The data suggest an increased level of consumption in an animal model of 
schizophrenia. Specifically, the NQ 10-10 group consumed significantly larger amounts of EtOH 
than the Saline group. This significant increase in EtOH consumption occurred only in adulthood 
beginning at PND 82 and lasted throughout the remainder of the study. The late onset of 
increased consumption in the NQ 10-10 group could have been due to solution palatability 
towards EtOH (Kiefer, 1995; Kiefer, Bice, & Badia-Elder, 1994). Previous studies (Kiefer & 
Dopp, 1989) have demonstrated that rats may habituate to the taste of EtOH after a prolonged 
exposure, which suggests that the taste towards EtOH has become less aversive.  
Taste reactivity tests are a way to measure the hedonic value an organism attributes to a 
gustatory stimulus (Kiefer & Dopp, 1989; for review see: Grill & Norgren, 1978). The 
palatability of a substance can have a great impact on future consummatory behaviors (Grill & 
Norgren, 1978). Specifically, concerning EtOH palatability in rats, EtOH concentrations 
exceeding 15% have been shown to result in a diminished interest towards the EtOH, which is 
represented as a lack of consumption (Kiefer et al., 1994). When conducting a two-bottle choice 
task (one bottle containing water, one bottle containing EtOH) diminished interest in the EtOH 
solution would result in an avoidance of the EtOH bottle and the subsequent consumption of 
mostly water (Kiefer, 1995; Kiefer & Dopp, 1989).  
In the current study, palatability could have affected the EtOH consumption amount of 
the NQ 10-20 and Saline groups due to the increased EtOH concentration between adolescence 
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(10%) and adulthood (20%). During adulthood, the two groups could have experienced aversive 
reactions towards the 20% EtOH consequently causing the diminished intake levels seen in 
Figure 2. Alternatively, the NQ 10-20 and Saline group could have increased their palatability 
for the taste of EtOH but the increase in consumption did not occur due to the postingestional 
factors associated with EtOH (Deutsch, Walton, & Thiel, 1978; Kiefer et al., 1994). However, 
the prolonged exposure to the 10% EtOH concentration in the NQ 10-10 group seemed to 
increase the palatability and decreases the aversion towards EtOH (Kiefer, 1995). The 
habituation towards the solution took effect on PND 82, in which a significant increase of EtOH 
consumption was observed for the remainder of the experiment. 
During the adolescent exposure period, all three treatment groups consumed similar 
amounts of EtOH. Even though one of the hypotheses of the present study suggested that NQ 
rats would consume more EtOH during adolescence the results of there not being a difference 
have been observed in previous research (Jeanblanc et al., 2014) as well. EtOH consumption in 
humans also suggest that adults consume more than adolescents, overall, but adolescents 
consume larger quantities of EtOH than adults on a single occasion (Spear, 2018). Since human 
adolescents exhibit a tendency to consume large amounts of EtOH over a small period of time, 
the assumption was that the adolescent rodents would show similar drinking behaviors. 
During adulthood, beginning on PND 83, the NQ 10-10 group diverged from the other 
treatment groups and chronically consumed more EtOH for the remainder of the study. 
Unfortunately, there was not a Saline control group to compare NQ 10-10 group’s EtOH 
consumption against. Since, there was not a control group for the NQ 10-10 group, the 
interpretations of the data must be limited. A study using a three-bottle (10% EtOH, 10% diluted 
white wine, & water) free-choice paradigm found that over a four-week period adult Sprague 
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Dawley females consumed on average 7.17 g/kg/week of combined white wine and 10% EtOH 
(Cacace, Plescia, Sardo, & Cannizzaro, 2012), which is significantly less than the amount of 
EtOH consumed by the NQ 10-10 group in the current study.     
Interestingly, the NQ 10-10 group exhibited a late onset of increased EtOH consumption, 
commencing at PND 82. From a neurobiological perspective, the phenomena could be a 
byproduct of neuroadaptation, by the brain trying to adapt to the effects of EtOH (Fadda & 
Rossetti, 1998; Himmelsbach, 1941). Neuroadaptation can be triggered by chronic EtOH 
administration and allows an organism to gain an increased tolerance to the substance. Increased 
tolerance to EtOH would explain the delayed increase in EtOH consumption in the NQ 10-10 
group (Fadda & Rossetti, 1998). 
Unfortunately, the NQ 10-20 group did not significantly differ from the Saline group in 
their ethanol consumption. The hypothesis that quinpirole would enhance EtOH consumption is 
because EtOH has been shown to enhance dopaminergic transmission in the brain, specifically 
from the VTA to the Acb (Di Chiara, 1997). EtOH enhances DA transmission directly, by 
increasing DA firing rate from the VTA to the Acb (Deehan et al., 2013; Deehan et al., 2016; 
Gilpin & Koob, 2008), and quinpirole super sensitizes D2-R in this pathway (Kostrezewa, 1993; 
Peterson et al., 2017) creating an enhanced response to the increased flow of DA due to EtOH 
consumption which would speculatively increase dependence to EtOH. Other factors namely, 
change of adulthood EtOH exposure, rat strain, and sex differences, could have also contributed 
to the insignificance in EtOH consumption between the NQ 10-20 group and the Saline group. 
Change of Adulthood EtOH Exposure Period 
The current study attempted to replicate a prior study (Jeanblanc et al., 2014) that 
increased the EtOH percentage from 10% to 20% from the adolescent exposure period to 
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adulthood. However, during the adulthood exposure period, the current study used an 
unrestricted free-choice paradigm while Jeanblanc et al. (2014) conducted an intermittent access 
two-bottle choice paradigm. The 20% intermittent access paradigm gives animals access to 
EtOH every other day for 24 hours (Jeanblanc, 2014; Simms et al., 2008, Wise, 1973). This 
method creates long-lasting high-EtOH preferencing by establishing an alcohol deprivation 
effect (ADE). The ADE is a transient increase in voluntary consumption compared to baseline 
due to the reinstatement of EtOH. The temporary increase in consumption allows rats to reach 
pharmacologically significant blood EtOH concentrations (BECs) (Simms et al., 2008; Sinclair, 
Hyytiä, & Nurmi, 1992). Thus, differing paradigms could be why different levels of 
consumption were seen between the two studies.    
Alternatively, the intake differences between groups could have been attributed to a floor 
effect in EtOH consumption. During adulthood, NQ 10-20 and Saline rats consumed similar 
amounts of EtOH, but the NQ 10-10 rats consumed significantly more EtOH than both groups. 
The difference in EtOH concentration could contribute to why the NQ 10-10 rats consumed 
significantly greater quantities of EtOH than the NQ 10-20 and Saline groups. Similarly, studies 
have shown that rats prefer EtOH concentrations ranging from 5 to 15% (Myers & Eriksson, 
1968). Although, a study assessing EtOH dose-response in Long-Evans rats, found that peak 
responding occurred during 10% and 20% EtOH concentrations indicating that these doses 
should exhibit similar reinforcing properties (Carnicella, Yowell, & Ron, 2011). Unless the 
reinforcing properties of EtOH are dependent on the strain of rat.  
Strain of Rat and EtOH Intake 
In the current study, the non-significance of EtOH consumption between the NQ 10-20 
and Saline groups could be attributed to a floor effect due to the rat strain used in the present 
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study (Carnicella, Ron, & Barak, 2014). Sprague Dawley rats were utilized because all previous 
NQ research used this rat strain (e.g. Brown et al., 2012; 2018a & b).  EtOH intake can vary 
tremendously depending on the strain of rat and even the supplier where that the rat was 
purchased (e.g. Hosová & Spear, 2018; Palm, Roman, & Nylander, 2011; Simms et al., 2008; for 
review see Carnicella et al., 2014). The most common outbred rat strain used for EtOH research 
is the Wistar rat and because of their superior EtOH intake capabilities, this strain has also been 
selectively bred to create lines of alcohol-preferring rats (e.g. Conte et al., 2019; Jadhav, 
Magistretti, Halfon, Augsburger & Boutrel, 2017; Momeni, Segerström & Roman, 2015; Palm et 
al., 2011; Priddy et al., 2017). However, some studies have used Long-Evans rats (e.g. Barak, 
Ahmadiantehrani, Kharazia, & Ron, 2011, Doherty, & Gonzales, 2015; Li, Bian, Dave, & Ye, 
2011; Simms et al., 2008) or Sprague Dawley rats (e.g. Bito-Onon, Simms, Chatterjee, Holgate, 
& Bartlett, 2011; Hosová & Spear, 2019; Li et al., 2019; Martinetti et al., 2006) to assess EtOH 
consumption. Even though the Wistar strain is the most commonly used rat strain for EtOH 
studies, researchers have differing opinions on whether the Wistar strain is the best rat to use for 
assessing EtOH consumption (Carnicella et al., 2014). With one study indicating that Sprague 
Dawley rats voluntarily consumed the same amount of EtOH as Wistar rats and significantly 
more EtOH than Long Evans Rats, using a sucrose fading paradigm (Gauvin, Moore, & 
Holloway,1993). Contrarily, a systematic review (Carnicella et al., 2014) on the EtOH 
consumption paradigm, intermittent access to EtOH in 2-bottle choice, concluded that Long-
Evans rats reached higher blood EtOH levels than other outbred rat strains. Other factors could 
result in outbred rat strains to consume different amounts of EtOH. The type of paradigm used to 
study EtOH consumption can greatly affect the amount consumed. For example, intermittent 
access to 20% EtOH in 2-bottle choice will result in higher levels of consumption than a 
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continuous access paradigm (Fu et al., 2015; Simms et al., 2008). Another factor that affects 
consummatory behaviors is if palatability enhancers, such as saccharin or sucrose, are added to 
the EtOH since it is known that rodents prefer sweet solutions (Boughter & Bachmanov, 2007; 
Crabbe, Phillips, & Belknap, 2010).       
Sex Differences and Quinpirole 
A potential issue in the current study could be that only female rats were used. Since 
sexual dimorphic behaviors are suggested in previous drug research utilizing the NQ model 
(Brown et al., 2011; Cope et al., 2010; Kostrzewa et al., 2016; Thacker et al., 2006), it will be 
important to further investigate whether sex differences are shown toward EtOH consumption 
behavior in the NQ model. Acute injections of quinpirole during adulthood revealed that rats 
injected with quinpirole yawn significantly more than those injected with saline, but male rats 
yawn significantly more than female rats injected with quinpirole (Cope et al., 2010; Kostrzewa 
et al., 2016; Thacker et al., 2006). This is important because yawning is a dopamine D2 receptor-
mediated event (Kostrzewa, Brus, Rykaczewska, & Plech, 1993; Kostrzewa et al., 2016). There 
are sex differences that reside in the development of the dopamine system, specifically in the 
Acb and striatum (Str). Male rats have been shown to have an increased level of D1 - R from 
adolescence into adulthood, while D2 - R levels in the Str seem to vary throughout adolescence 
until approximately P60 when D2 - R levels stabilize and are similar to female expression 
(Andersen & Teicher, 2000; Kostrzewa et al., 2016). Studies have assessed whether the 
differences in DA levels are great enough to cause any sexual dimorphic behaviors in NQ rats, 
with results suggesting female rats exhibit a reduced conditioned effect but an enhanced 
behavioral activation to nicotine compared to male rats (Sheppard, Lehmann, Cope, & Brown, 
2009). Additionally, research demonstrated that female NQ rats acutely treated with 
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methylphenidate manifest significantly higher levels of locomotor activity, increased response, 
and sensitization as opposed to male NQ rats (Cope et al., 2010). Interestingly, past work has 
also revealed that adult female rats have been shown to consume more EtOH than adult male rats 
(Alemedia et al., 1998; Priddy et al., 2017; Vetter-O’Hagen, Varlinskaya, & Spear, 2009). 
Further investigations are required to assess the gender variations in NQ EtOH consummatory 
behaviors.  
Body Weight, Food, and Water 
Bodyweight, food consumption, and water intake were recorded daily and analyzed to 
view any variations between groups and the relationship between these variables and EtOH 
consumption. NQ 10-20 rats weighed significantly more than Saline rats. Additionally, both 
groups treated with quinpirole weighed significantly more than the Saline group throughout 
adulthood. This finding correlates with the clinical population of schizophrenia that suggests that 
the elevated risk of weight gain is perhaps due to dysfunction in anticipatory reward processing 
in the striatum (Grimm, Kaiser, Plichta, & Tobler, 2017). The NQ 10-20 Treatment group was 
also found to have consumed significantly more food than the NQ 10-10 and Saline Treatment 
Groups. Studies have examined the relationship between food intake and EtOH consumption 
finding that rats will decrease food consumption in direct proportion to EtOH intake (Larue-
Achagiotis, Paussard, & Louis-Sylvestre, 1990; Richardson, Rumsey, & Read, 1990). NQ 10-10 
rats were consuming increased quantities of EtOH compared to the NQ 10-20 group or Saline 
group, thus possibly reducing their food intake. Also, the differences in food consumption 
between groups could have been a byproduct of changing the manner of how the food was 
administered to the rats. For NQ 10-20 rats, the food was placed on top of the rats’ cages but for 
the NQ 10-10 and Saline rats, the food pellets were placed in a hanging food hopper inside the 
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rats’ cages. Intriguingly, Saline rats significantly consumed more water than the NQ 10-20 rats 
but not the NQ 10-10 rats. Perhaps the 20% EtOH was less appealing to the Saline rats than the 
NQ 10-20 rats. The current study’s hypotheses were partially supported in that the NQ 10-10 
group did significantly consume more EtOH than the Saline group; but only during adulthood 
and the EtOH concentrations were different, NQ 10-10 rats received 10% EtOH and the Saline 
rats received 20% EtOH.     
Conclusion 
Overall, the data partially support the proposed hypotheses and provides further evidence 
that EtOH consumption during adolescence significantly increases the amount of EtOH 
consumed during adulthood. The data from the NQ 10-10 group seems promising in providing 
partial evidence that NQ rats are a valid model for assessing EtOH consumption. Schizophrenia 
is a detrimental psychiatric disorder that has a high disease burden due to premature mortality 
(Hjorthøj et al., 2017). Several factors contribute to the elevated risk of mortality, namely the 
increased frequency of drug abuse (APA, 2014; Green et al., 2007). Specifically, AUD effects 
upwards to 65% of the schizophrenic population magnifying negative health outcomes (Volkow, 
2009). Investigations have revealed that the elevated risk of AUD comorbid schizophrenia is due 
to similar neuronal pathways being affected in both disorders (Nestler et al., 2015). This is the 
first time the NQ model has been implemented to assess EtOH consumption using the two-bottle 
choice task with two-exposure periods. Future studies will be needed to provide an enhanced 
knowledge of AUD comorbid schizophrenia by using the NQ model of schizophrenia.    
Future Directions 
Future studies will aim to replicate the current study to increase the power and effect size 
in hopes that this will delineate EtOH consumption between the NQ rats and Saline rats, as well 
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as using male Sprague Dawley rats to examine the potential effect of sex differences on NQ 
drinking behavior. Furthermore, an additional saline neonatal treatment group in which the 
adulthood EtOH concentration is reduced from 20% to 10% needs to be implemented to extend 
the interpretation of the adulthood drinking data for the NQ 10-10 animals. Results from the NQ 
10-10 rats consuming an EtOH concentration of 10% seem very promising (shown in Figure 1) 
but the evaluation of a control group must occur prior to any further inferences. A study 
examining the effect of EtOH consumption only during adulthood in the NQ model would 
provide valuable insight concerning whether the adolescent exposure period is a key factor for 
increased EtOH consumption later in life. Rodent model research results have shown mixed 
findings on the significance of EtOH consumption during adolescence. Some studies indicate 
that EtOH consumption during adolescence increases drinking behavior in adulthood (Amodeo, 
Kneiber, Wills, & Ehlers, 2017; Gilpin, Karanikas, & Richardson, 2012), while others have not 
found significant differences in rats that were exposed to EtOH in adolescence versus those that 
were not (Slawecki & Betancourt, 2002; Vetter, Doremus-Fitzwater, & Spear, 2007). 
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